Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery

Published:2012-10 Issue:17 Volume:60 Page:1623-1630
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Varenhorst Christoph,Alström Ulrica,Scirica Benjamin M.,Hogue Charles W.,Åsenblad Nils,Storey Robert F.,Steg Ph. Gabriel,Horrow Jay,Mahaffey Kenneth W.,Becker Richard C.,James Stefan,Cannon Christopher P.,Brandrup-Wognsen Gunnar,Wallentin Lars,Held Claes

Funder

AstraZeneca

Merck

Johnson & Johnson

Bayer

Daiichi Sankyo

Bristol-Myers Squibb

Gilead Sciences

Novartis

Boehringer Ingelheim

Eli Lilly & Company

GlaxoSmithKline

Pozen

Regado Biotechnologies

Sanofi Aventis

Schering Plough

The Medicines Company

MSD

Accumetrics

Essentialis

Regeneron

Takeda

Merck/Schering-Plough

Boehringer-Ingelheim

Bristol-Myers Squibb/Pfizer

Schering-Plough/Merck

Roche

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference23 articles.

1. Ticagrelor versus clopidogrel in patients with acute coronary syndromes;Wallentin;N Engl J Med,2009

2. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial;Held;J Am Coll Cardiol,2011

3. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy;Schneider;J Am Coll Cardiol,2011

4. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial;James;Am Heart J,2009

5. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: Summary Article

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating ticagrelor in a preclinical pipeline as a novel therapeutic to prevent preterm birth;Reproduction;2024-01-11

2. Ticagrelor alleviates pyroptosis of myocardial ischemia reperfusion-induced acute lung injury in rats: a preliminary study;PeerJ;2024-01-04

3. Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis;European Heart Journal;2023-07-13

4. Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1;Frontiers in Cardiovascular Medicine;2023-01-06

5. Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review;Journal of Thoracic Disease;2022-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3